RRMS
MCID: RLP002
MIFTS: 58

Relapsing-Remitting Multiple Sclerosis (RRMS)

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

MalaCards integrated aliases for Relapsing-Remitting Multiple Sclerosis:

Name: Relapsing-Remitting Multiple Sclerosis 12 15
Multiple Sclerosis, Relapsing-Remitting 44 73
Relapsing Remitting Multiple Sclerosis 29 6
Relapsing-Remitting Ms 12 15
Multiple Sclerosis Relapsing-Remitting 55
Rrms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2378
MeSH 44 D020529
UMLS 73 C0751967

Summaries for Relapsing-Remitting Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). Symptoms may vary from mild to severe, and relapses and remissions may last for days or months. More than 80 percent of people who have MS begin with relapsing-remitting cycles.

MalaCards based summary : Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to optic neuritis and multiple sclerosis. An important gene associated with Relapsing-Remitting Multiple Sclerosis is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Natalizumab and Interferon beta-1b have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are hematopoietic system and growth/size/body region

Related Diseases for Relapsing-Remitting Multiple Sclerosis

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 optic neuritis 30.7 AQP4 MBP MOG TNF
2 multiple sclerosis 30.6 TNF TIMP1 MX1 MOG MMP9 MBP
3 microscopic polyangiitis 30.6 IL10 TNF
4 hematopoietic stem cell transplantation 30.5 IFNG IL10 TNF
5 influenza 30.5 CCL5 IFNB1 IFNG MX1
6 chlamydia 30.5 IFNG IL10 IL4 TNF
7 idiopathic neutropenia 30.4 CCL5 IL10 TNF
8 secondary progressive multiple sclerosis 30.4 HNRNPA1 IFNB1 IFNG IL10 MBP MMP9
9 neuritis 30.3 AQP4 CCL5 IFNG IL4 MBP MOG
10 neuromyelitis optica 30.3 AQP4 IL17A MBP MOG
11 acute disseminated encephalomyelitis 30.1 AQP4 IL10 MBP MOG
12 lung disease 30.1 CCL5 IL10 IL17A MMP9 TNF
13 asthma 29.2 BDNF CCL5 ICAM1 IFNG IL10 IL17A
14 depression 10.6
15 marburg hemorrhagic fever 10.4 IFNB1 TNF
16 multifocal choroiditis 10.4 IL10 TNF
17 punctate inner choroidopathy 10.4 IL10 TNF
18 cephalosporin allergy 10.4 IFNG IL10
19 staphylococcal toxic shock syndrome 10.4 IFNG TNF
20 palladium allergic contact dermatitis 10.3 IL10 IL17A
21 neonatal hypoxic and ischemic brain injury 10.3 BDNF MBP
22 autoimmune atherosclerosis 10.3 FOXP3 IL10
23 anxiety 10.3
24 spasticity 10.3
25 acute necrotizing encephalitis 10.3 FOXP3 IFNG
26 encephalitozoonosis 10.3 MX1 TNF
27 scorpion envenomation 10.3 CCL5 TNF
28 allergic encephalomyelitis 10.3 MBP MOG
29 graft-versus-host disease 10.3 IFNG IL10 TNF
30 dengue hemorrhagic fever 10.3 IFNG IL10 TNF
31 necrotizing ulcerative gingivitis 10.3 IL10 IL18
32 osteomyelitis 10.3 IFNG IL10 TNF
33 hepatitis a 10.3 IFNG IL10 TNF
34 chagas disease 10.3 IFNG IL10 TNF
35 leptospirosis 10.3 IFNG IL10 TNF
36 testicular disease 10.3 IFNG IL10 TNF
37 mixed connective tissue disease 10.3 IFNG IL10 TNF
38 multiple sclerosis 2 10.3
39 thrombocytopenia 10.3
40 panuveitis 10.3 IL10 IL17A TNF
41 uveal disease 10.3 IL10 IL17A TNF
42 otitis media 10.3 IL10 IL4 TNF
43 rheumatic heart disease 10.3 IL10 IL4 TNF
44 keratoconjunctivitis sicca 10.3 IL10 IL4 TNF
45 aggressive periodontitis 10.3 IL10 IL4 TNF
46 gastroenteritis 10.3 IL10 IL4 TNF
47 tonsillitis 10.3 IFNG IL4 TNF
48 parasitic helminthiasis infectious disease 10.3 IL10 IL4 TNF
49 aphthous stomatitis 10.3 IL10 IL4 TNF
50 ige responsiveness, atopic 10.3 IFNG IL10 IL4

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to Relapsing-Remitting Multiple Sclerosis

Symptoms & Phenotypes for Relapsing-Remitting Multiple Sclerosis

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.37 AQP4 CCL5 FOXP3 ICAM1 IFNB1 IFNG
2 growth/size/body region MP:0005378 10.36 AQP4 BDNF FOXP3 ICAM1 IFNG IL10
3 immune system MP:0005387 10.33 AQP4 CCL5 FOXP3 ICAM1 IFNB1 IFNG
4 homeostasis/metabolism MP:0005376 10.32 AQP4 BDNF FOXP3 ICAM1 IFNB1 IFNG
5 cellular MP:0005384 10.3 BDNF FOXP3 ICAM1 IFNG IL10 IL18
6 digestive/alimentary MP:0005381 10.28 AQP4 BDNF FOXP3 ICAM1 IFNG IL10
7 endocrine/exocrine gland MP:0005379 10.22 AQP4 BDNF FOXP3 ICAM1 IFNG IL10
8 mortality/aging MP:0010768 10.22 AQP4 BDNF FOXP3 ICAM1 IFNG IL10
9 nervous system MP:0003631 10.1 AQP4 BDNF ICAM1 IFNB1 IFNG IL10
10 craniofacial MP:0005382 10.09 BDNF FOXP3 IFNG IL10 IL17A IL4
11 integument MP:0010771 10.09 BDNF FOXP3 ICAM1 IFNG IL10 IL18
12 neoplasm MP:0002006 9.91 ICAM1 IFNB1 IFNG IL10 MMP9 TIMP1
13 no phenotypic analysis MP:0003012 9.91 AQP4 BDNF FOXP3 IFNB1 IFNG IL10
14 reproductive system MP:0005389 9.81 BDNF FOXP3 IFNG IL10 IL4 MBP
15 respiratory system MP:0005388 9.65 AQP4 BDNF FOXP3 IFNG IL10 IL17A
16 vision/eye MP:0005391 9.4 AQP4 BDNF FOXP3 ICAM1 IFNG IL10

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

Drugs for Relapsing-Remitting Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
2
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
3
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
4
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2 216503-57-0
5
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
6
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 637568 5271565
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Cetirizine Approved Phase 4 83881-51-0 2678
9
Acyclovir Approved Phase 4,Phase 3 59277-89-3 2022
10
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 51-45-6, 75614-87-8 774
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
13
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
14
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
16
Ranitidine Approved Phase 4,Phase 3 66357-35-5, 66357-59-3 3001055
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
19
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
20
Iron Approved Phase 4 7439-89-6 23925
21
Phytonadione Approved, Investigational Phase 4,Phase 3 84-80-0 4812 5284607
22
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
23
Titanium dioxide Approved Phase 4 13463-67-7
24
Donepezil Approved Phase 4 120014-06-4 3152
25
Mitoxantrone Approved, Investigational Phase 4,Phase 2 65271-80-9 4212
26
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
27
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
28
Norepinephrine Approved Phase 4 51-41-2 439260
29
Citalopram Approved Phase 4 59729-33-8 2771
30
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
31
Simethicone Approved Phase 4 8050-81-5
32
Loperamide Approved Phase 4 53179-11-6 3955
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
34
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
36
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 67-97-0 5280795 6221
37
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 50-14-6 5280793
38
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
39
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
40
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2 2920-86-7
41 Tocotrienol Investigational Phase 4 6829-55-6
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Fingolimod Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46
Glatiramer Acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 147245-92-9 3081884
47 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 retinol Phase 4

Interventional clinical trials:

(show top 50) (show all 423)
# Name Status NCT ID Phase Drugs
1 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
4 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
5 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
6 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
7 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
8 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
9 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
10 Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis Completed NCT02461069 Phase 4 Dimethyl fumarate
11 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Completed NCT00871780 Phase 4 BG00002 (natalizumab)
12 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
13 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4 Betaferon/Betaseron;Rebif;Betaferon/Betaseron
14 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4 Rebif®;Copaxone®
15 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
16 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Completed NCT01498887 Phase 4 Fingolimod (FTY720)
17 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
18 Plegridy Satisfaction Study in Participants Completed NCT02587065 Phase 4 peginterferon beta-1a
19 Natalizumab De-escalation With Interferon Beta-1b Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
20 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
21 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
22 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
23 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
24 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
25 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
26 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
27 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies Completed NCT00492466 Phase 4 Interferon-beta-1a;methylprednisolone
28 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis Completed NCT00367484 Phase 4
29 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
30 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis Completed NCT01395316 Phase 4 Alemtuzumab
31 MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Completed NCT01633112 Phase 4 fingolimod;copaxone
32 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo
33 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Completed NCT02499900 Phase 4 Copaxone®
34 Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? Completed NCT00534261 Phase 4 Interferon beta-1a
35 Fingolimod -Response According to Coping - Evaluation Completed NCT01420055 Phase 4 fingolimod
36 FOCUS Fatigue Outcome in Copaxone USers Completed NCT00267319 Phase 4 Glatiramer acetate
37 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4 Interferon beta 1a, oral doxycycline
38 Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial Completed NCT01085318 Phase 4 Rebif
39 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
40 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy Completed NCT03091569 Phase 4
41 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
42 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4 Placebo
43 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4 Donepezil HCI (drug)
44 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
45 STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) Completed NCT01585298 Phase 4 FTY720
46 An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS Completed NCT00206648 Phase 4 Betaferon/Betaseron;Betaferon/Betaseron
47 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
48 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4 Fingolimod
49 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
50 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: multiple sclerosis, relapsing-remitting

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

Genetic tests related to Relapsing-Remitting Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Relapsing Remitting Multiple Sclerosis 29

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

41
Brain, T Cells, Testes, Bone, B Cells, Spinal Cord, Monocytes

Publications for Relapsing-Remitting Multiple Sclerosis

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50) (show all 1302)
# Title Authors Year
1
Cortical Excitability and Interhemispheric Connectivity in Early Relapsing-Remitting Multiple Sclerosis Studied With TMS-EEG. ( 29937712 )
2018
2
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study. ( 29796290 )
2018
3
Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics. ( 29285552 )
2018
4
Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-I^-Treated Relapsing-Remitting-Multiple Sclerosis Patients. ( 29915590 )
2018
5
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). ( 29399053 )
2018
6
Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis. ( 29898076 )
2018
7
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. ( 29406907 )
2018
8
Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab. ( 29907474 )
2018
9
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE). ( 29431876 )
2018
10
Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis. ( 29300420 )
2018
11
Late onset and young onset relapsing remitting multiple sclerosis. Evidence from a retrospective long-term follow-up study. ( 29956427 )
2018
12
Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients. ( 29390025 )
2018
13
Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study. ( 29928468 )
2018
14
Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. ( 29867923 )
2018
15
Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. ( 29297273 )
2018
16
Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis. ( 29306401 )
2018
17
Thalamus volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients. ( 29869576 )
2018
18
Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment. ( 29896193 )
2018
19
Synchronization within, and interactions between, the default mode and dorsal attention networks in relapsing-remitting multiple sclerosis. ( 29795982 )
2018
20
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al. ( 29308979 )
2018
21
Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2A Lesion Load : AA 3-Tesla Magnetic Resonance Imaging Study. ( 29299614 )
2018
22
Biomarkers identification for PML monitoring, during Natalizumab (TysabriAr) treatment in Relapsing-Remitting Multiple Sclerosis. ( 29353737 )
2018
23
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. ( 29363337 )
2018
24
Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. ( 29866196 )
2018
25
Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. ( 29911917 )
2018
26
When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis. ( 29923439 )
2018
27
Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis. ( 29348591 )
2018
28
Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis. ( 29885597 )
2018
29
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. ( 29399054 )
2018
30
Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies? ( 29411688 )
2018
31
Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224]. ( 29449007 )
2018
32
Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis. ( 29882035 )
2018
33
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. ( 29971666 )
2018
34
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis? ( 29308975 )
2018
35
IL12B gene polymorphisms have sex-specific effects in relapsing-remitting multiple sclerosis. ( 30554348 )
2018
36
Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases. ( 30557092 )
2018
37
Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'. ( 30557095 )
2018
38
Reasons for nonadherence and response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients. ( 30485422 )
2018
39
Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey. ( 30496233 )
2018
40
Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. ( 30498433 )
2018
41
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. ( 30522373 )
2018
42
No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients. ( 30429773 )
2018
43
Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study. ( 30445232 )
2018
44
C/EBP homologous protein investigation in the serum and cerebro-spinal fluid of relapsing-remitting multiple sclerosis patients. ( 30446370 )
2018
45
Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod? ( 30447536 )
2018
46
Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA. ( 30451064 )
2018
47
Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis. ( 30453199 )
2018
48
Evaluating sex hormones and cytokine profile in Egyptian females with relapsing-remitting multiple sclerosis. ( 30459503 )
2018
49
Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. ( 30476873 )
2018
50
Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. ( 30479356 )
2018

Variations for Relapsing-Remitting Multiple Sclerosis

ClinVar genetic disease variations for Relapsing-Remitting Multiple Sclerosis:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.755G> A (p.Ser252Asn) single nucleotide variant Uncertain significance rs483353020 GRCh37 Chromosome 12, 54677599: 54677599
2 HNRNPA1 NM_002136.3(HNRNPA1): c.755G> A (p.Ser252Asn) single nucleotide variant Uncertain significance rs483353020 GRCh38 Chromosome 12, 54283815: 54283815
3 HNRNPA1 NM_002136.3(HNRNPA1): c.775A> G (p.Ser259Gly) single nucleotide variant Uncertain significance rs483353021 GRCh37 Chromosome 12, 54677619: 54677619
4 HNRNPA1 NM_002136.3(HNRNPA1): c.775A> G (p.Ser259Gly) single nucleotide variant Uncertain significance rs483353021 GRCh38 Chromosome 12, 54283835: 54283835
5 HNRNPA1 NM_002136.3(HNRNPA1): c.826A> C (p.Met276Leu) single nucleotide variant Likely pathogenic rs483353024 GRCh37 Chromosome 12, 54677670: 54677670
6 HNRNPA1 NM_002136.3(HNRNPA1): c.826A> C (p.Met276Leu) single nucleotide variant Likely pathogenic rs483353024 GRCh38 Chromosome 12, 54283886: 54283886
7 HNRNPA1 NM_002136.3(HNRNPA1): c.839A> G (p.Asn280Ser) single nucleotide variant Likely pathogenic rs3207617 GRCh37 Chromosome 12, 54677683: 54677683
8 HNRNPA1 NM_002136.3(HNRNPA1): c.839A> G (p.Asn280Ser) single nucleotide variant Likely pathogenic rs3207617 GRCh38 Chromosome 12, 54283899: 54283899
9 HNRNPA1 NM_002136.3(HNRNPA1): c.937A> G (p.Ser313Gly) single nucleotide variant Likely benign rs483353026 GRCh37 Chromosome 12, 54678071: 54678071
10 HNRNPA1 NM_002136.3(HNRNPA1): c.937A> G (p.Ser313Gly) single nucleotide variant Likely benign rs483353026 GRCh38 Chromosome 12, 54284287: 54284287
11 HNRNPA1 NM_002136.3(HNRNPA1): c.940T> C (p.Tyr314His) single nucleotide variant Likely benign rs483353027 GRCh37 Chromosome 12, 54678074: 54678074
12 HNRNPA1 NM_002136.3(HNRNPA1): c.940T> C (p.Tyr314His) single nucleotide variant Likely benign rs483353027 GRCh38 Chromosome 12, 54284290: 54284290
13 HNRNPA1 NM_002136.3(HNRNPA1): c.955A> G (p.Arg319Gly) single nucleotide variant Likely benign rs3206707 GRCh37 Chromosome 12, 54678089: 54678089
14 HNRNPA1 NM_002136.3(HNRNPA1): c.955A> G (p.Arg319Gly) single nucleotide variant Likely benign rs3206707 GRCh38 Chromosome 12, 54284305: 54284305

Expression for Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for Relapsing-Remitting Multiple Sclerosis

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CCL5 ICAM1 IFNB1 IFNG IL10 IL17A
2
Show member pathways
13.71 BDNF CCL5 IFNB1 IFNG IL10 IL17A
3
Show member pathways
13.58 BDNF CCL5 ICAM1 IFNB1 IFNG IL10
4
Show member pathways
13.44 BDNF CCL5 IL10 IL17A IL18 IL4
5
Show member pathways
13.33 BDNF CCL5 IL10 IL17A IL18 IL4
6
Show member pathways
13.32 CCL5 ICAM1 IFNB1 IFNG IL10 IL17A
7
Show member pathways
13.04 CCL5 IFNB1 IFNG IL10 IL18 TNF
8
Show member pathways
12.94 FOXP3 ICAM1 IFNG IL10 IL17A IL18
9
Show member pathways
12.85 CCL5 ICAM1 IFNB1 IFNG IL18 IL4
10
Show member pathways
12.78 CCL5 IFNB1 IFNG IL18 TNF
11
Show member pathways
12.67 FOXP3 IFNG IL10 IL17A IL18 IL4
12
Show member pathways
12.66 IFNG IL10 IL18 IL4 TNF
13
Show member pathways
12.64 IFNG IL10 IL17A IL18 TIMP1 TNF
14 12.63 CCL5 FOXP3 IFNG IL10 IL17A IL4
15
Show member pathways
12.56 ICAM1 IFNB1 IFNG IL4 TNF
16
Show member pathways
12.48 IFNG IL10 IL17A IL4 TNF
17
Show member pathways
12.39 CCL5 ICAM1 IFNG IL4 TNF
18
Show member pathways
12.38 IFNG IL17A IL4 MMP9 TNF
19 12.29 IFNB1 IFNG IL10 IL18 TNF
20
Show member pathways
12.28 IFNG IL10 IL4 TNF
21
Show member pathways
12.23 BDNF IFNB1 IFNG IL10 IL17A IL18
22
Show member pathways
12.22 IFNB1 IFNG IL4 TNF
23 12.21 AQP4 BDNF IL10 TNF
24 12.13 ICAM1 IFNG MMP9 TNF
25
Show member pathways
12.13 IFNG IL10 IL17A IL18 TNF
26
Show member pathways
12.08 IFNG IL4 MMP9 TNF
27 12.05 CCL5 ICAM1 IFNB1 MMP9 TNF
28 12.04 IFNG IL10 IL4 TNF
29
Show member pathways
12.03 BDNF CCL5 ICAM1 IFNG IL10 IL17A
30 11.94 CCL5 ICAM1 IFNG IL17A IL18 TNF
31 11.94 AQP4 BDNF ICAM1 IFNG IL4 MBP
32 11.88 IFNG IL10 TNF
33
Show member pathways
11.86 FOXP3 ICAM1 IL17A
34 11.86 IFNG IL10 IL17A IL18 IL4 TNF
35
Show member pathways
11.83 FOXP3 IFNG IL4 TNF
36 11.81 IFNB1 IFNG IL10 TNF
37 11.81 ICAM1 IL10 IL17A IL18 IL4 MMP9
38 11.8 ICAM1 IFNG IL4
39 11.74 CCL5 IL4 MMP9 TIMP1 TNF
40
Show member pathways
11.73 ICAM1 IFNG MMP9 TNF
41 11.62 ICAM1 IFNG IL10 IL18 TNF
42 11.59 FOXP3 IFNG IL10 IL4
43 11.56 ICAM1 MMP9 TNF
44 11.56 IFNG IL18 TNF
45 11.47 ICAM1 IFNG IL10 IL18 TNF
46 11.43 ICAM1 IFNB1 IFNG
47 11.4 IFNG IL17A IL18 IL4 TNF
48 11.32 IFNB1 IFNG IL10 IL4 TNF
49 11.29 CCL5 IL10 IL17A IL18 IL4 TNF
50 11.25 IFNG IL10 IL4

GO Terms for Relapsing-Remitting Multiple Sclerosis

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 BDNF CCL5 IFNB1 IFNG IL10 IL17A
2 external side of plasma membrane GO:0009897 9.55 AQP4 ICAM1 IL17A MOG TNF
3 extracellular space GO:0005615 9.4 BDNF CCL5 ICAM1 IFNB1 IFNG IL10

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CCL5 IL10 IL17A IL18 TNF
2 MAPK cascade GO:0000165 9.96 CCL5 IL18 MBP TNF
3 response to organic substance GO:0010033 9.86 IL10 TIMP1 TNF
4 immune response GO:0006955 9.86 CCL5 IFNG IL10 IL17A IL18 IL4
5 cellular response to interleukin-1 GO:0071347 9.85 CCL5 ICAM1 IL17A
6 B cell differentiation GO:0030183 9.84 IFNB1 IL10 IL4
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 CCL5 IL18 TNF
8 cellular response to organic cyclic compound GO:0071407 9.83 CCL5 IL18 TNF
9 regulation of insulin secretion GO:0050796 9.83 CCL5 IFNG TNF
10 humoral immune response GO:0006959 9.79 IFNB1 IFNG TNF
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 CCL5 IL18 TNF
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.75 IL10 MMP9 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 ICAM1 IFNG TNF
14 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 ICAM1 IL10 IL4
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CCL5 IFNG IL18 IL4
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.7 CCL5 IL18 TNF
17 negative regulation of interleukin-17 production GO:0032700 9.68 FOXP3 IFNG
18 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 IL10 MBP
19 neutrophil activation GO:0042119 9.67 CCL5 IL18
20 negative regulation of viral genome replication GO:0045071 9.67 CCL5 IFNB1 MX1 TNF
21 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
22 negative regulation of interleukin-6 production GO:0032715 9.65 FOXP3 IL10 TNF
23 regulation of signaling receptor activity GO:0010469 9.65 BDNF CCL5 IFNB1 IFNG IL10 IL17A
24 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.64 IL10 TIMP1
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
26 response to virus GO:0009615 9.63 CCL5 FOXP3 IFNB1 IFNG MX1 TNF
27 positive regulation of receptor binding GO:1900122 9.62 BDNF MMP9
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
29 positive regulation of osteoclast differentiation GO:0045672 9.61 IFNG IL17A TNF
30 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.6 ICAM1 TNF
31 positive regulation of neuroinflammatory response GO:0150078 9.59 IL18 TNF
32 positive regulation of interleukin-23 production GO:0032747 9.57 IFNG IL17A
33 regulation of isotype switching GO:0045191 9.55 IL10 IL4
34 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
35 type 2 immune response GO:0042092 9.5 IL10 IL18 IL4
36 receptor biosynthetic process GO:0032800 9.49 IL10 TNF
37 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 IFNG TNF
38 cytokine-mediated signaling pathway GO:0019221 9.32 CCL5 ICAM1 IFNB1 IL10 IL17A IL18
39 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 FOXP3 IFNB1 IL10 IL17A IL18 IL4
40 positive regulation of gene expression GO:0010628 10.04 FOXP3 IFNG IL18 IL4 TNF

Molecular functions related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 CCL5 IFNB1 IFNG IL10 IL17A IL18
2 growth factor activity GO:0008083 9.26 BDNF IL10 IL4 TIMP1